Bristol-Myers Squibb Co (NYSE:BMY) is a $103.5 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader's current ranking for BMY puts it 64 among the 134 companies in this industry group, placing it in the top half. BMY is ranked in the top half of the sector with a ranking of 370 among the 782 companies in the sector and number 2,185 in the 5000 company Portfolio Grader company universe.

The current recommendation of Hold for Bristol-Myers Squibb Co (NYSE:BMY) is derived using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. BMY has maintained this ranking for 2 months.

Bristol-Myers Squibb Co (NYSE:BMY) is ranked as a Hold using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BMY has had from Portfolio Grader for 2 months.

The current recommendation of Hold for Bristol-Myers Squibb Co (NYSE:BMY) has been derived by using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. BMY has maintained this ranking for 2 months.

The current recommendation of Hold for Bristol-Myers Squibb Co (NYSE:BMY) is the result of using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing system. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

Currently, Bristol-Myers Squibb Co (NYSE:BMY) has a Hold using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

The current recommendation of Buy for Bristol-Myers Squibb Co (NYSE:BMY) is derived using Louis Navellier's approach to investing and his Portfolio Grader stock evaluator. BMY has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Bristol-Myers Squibb Co (NYSE:BMY) is a constituent of the 135 company Pharmaceuticals GICS industry group, which is part of the 783 company GICS Health Care sector. BMY's market value is $107.1 billion which falls in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 32 among the 135 companies in this industry group, giving it a well above-average position; in the top half of the sector with a ranking of 225 among the 783 companies in the sector, and number 1,631 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks Bristol-Myers Squibb Co (NYSE:BMY) a Hold. With exclusive fundamental and quantitative analytical tools developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The shares have been upgraded from a Sell to a Hold in the last week.